![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 28, 2018 6:42:30 AM
Published: Sept 28, 2018 2:40 a.m. ET
goetzpartners securities Limited
Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-T
28-Sep-2018 / 07:39 GMT/BST
Free to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.Published to the market and investors on 28th September 2018 @ 7.17am (London time).Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-TRecommendation: OUTPERFORMTarget Price: USD$4.00 Current Price: USD$0.76 (COB on 27th September 2018) KEY TAKEAWAYWith its molecular-targeted radio-therapy Iomab-B showing promise and in a pivotal Phase III for bone marrow transplant, Actinium has initiated a programme to use lower dose (Iomab-ACT) to boost safety and efficacy of the much-vaunted CAR-T therapy in blood cancers. While the tens of billions USD spent on CAR-T assets highlight the potential, the extreme cost and safety concerns surrounding CAR-T have so far held back uptake of the two marketed products Kymriah (Novartis) and Yescarta (Kite Pharma / Gilead). Based on previous data, Actinium believes that replacing the current toxic pre-CAR-T conditioning regimen with targeted radiotherapy could improve patient outcomes, potentially reducing barriers to reimbursement and expanding patient access. Although the true scale of the CAR-T Iomab-ACT opportunity is unclear at this early stage, Actinium's new initiative further highlights the potential of its molecular-targeted radiotherapy in blood and immune diseases. We maintain and reiterate both our OUTPERFORM recommendation and TP of $4.00 / share as detailed in our initiation report of April 2018.Benefits of Iomab-ACT over chemo - Successful CAR-T therapy requires depletion of patient lymphocytes prior to treatment. Iomab-ACT therapy promises to provide specific targeting of lymphocytes, including cancer cells, provided by one dose in an out-patient setting. Current fludaribine / cyclophosphamide ("Flu-Cy") leads to non-specific blood cell depletion as well as other toxicity and requires multiple infusions over a number of days. Iomab-ACT has the potential for better efficacy, safety and convenience.CAR-T benefits come at a cost - The benefits of the already marketed products Kymriah and Yescarta in helping otherwise hopeless patients beat treatment refractory blood cancers including acute lymphoblastic leukaemia ("ALL"), diffuse large cell lymphoma ("DLCL") are well known. However, the enormous cost of manufacturing and supplying these personalised therapies (treatment costs approaching $500k) presents a significant barrier to reimbursement.Improved outcomes could facilitate reimbursement - Given the sky-high cost, payers increasing looking towards outcome-based reimbursement schemes for CAR-T based therapies. The improved safety and efficacy promised by Iomab-ACT compared to existing chemotherapeutic Flu-Cy regimens could facilitate such an outcome-based approach.Documented safety and efficacy of Iomab - Low dose Iomab has already been shown to deplete lymphocytes and is safe at much greater doses as documented in over 500 patients undergoing pre-bone marrow transplant conditioning. While Actinium has yet to disclose details, a relatively simple dosing trial of Iomab-ACT in combination with CAR-T is in planning by its clinical collaborators.Providing CAR-T players with freedom to operate - Flu-Cy lymphocyte depletion regimens for CAR-T is covered by a patent filed by Kite Pharma (owned by Gilead). An effective alternative conditioning pathway patented by Actinium could provide other CAR-T players freedom to operate.Significant upside - The prospect of significant clinical news flow from Actimab in H2/2018E and pivotal readout on Iomab-B suggests significant upside from current levels. As detailed in our initiation report of April 2018, our valuation suggests that Actinium still remains fundamentally undervalued at current levels. Our analysis indicates a current fair value of $2.60 per share rising to $5.00 per share on the back of positive phase 2 data in H2/2018E. We maintain and reiterate both our OUTPERFORM recommendation and target price of $4.00 per share.Kind regards, Chris Redhead | Analystgoetzpartners Healthcare Research Team | Research Teamgoetzpartners securities LimitedThe Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.T +44 (0) 203 859 7725 | chris.redhead@goetzpartners.com / healthcareresearch@goetzpartners.comwww.goetzpartnerssecurities.comRegistered in England No. 04684144.Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.Click here to see our privacy policy.GPSL has a formal client relationship with Actinium Pharmaceuticals Inc.GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority ("FCA"). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).In accordance with the General Data Protection Regulation ("GDPR") - if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:researchproduction@goetzpartners.comAbout GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.This e-mail (including any attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (firm reference number:225563).Click on the following link for the GPSL MiFID2 Investor Guidance NoticeGPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.Please copy the below link and paste it into your browser for the full pdf version of the equity research report:https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=26b46358-9d60-4488-8ee3-4d544570c416&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryViewFree to access research and investor meetings in a post-MiFID2 world.This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
728461 28-Sep-2018
DISCLAIMER: MY POSTS ARE STRICTLY MY OPINION, AND ANY OPINION
PROVIDED DOES NOT CONSTITUTE A BUY,SELL, OR HOLD RECOMMENDATION OR DECISION.
.
Please feel free to respond to my Posts.
.
Make it and don't get fooled by others.
Recent ATNM News
- Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial • PR Newswire (US) • 06/14/2024 12:30:00 PM
- Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/11/2024 12:30:00 PM
- Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity • PR Newswire (US) • 05/15/2024 12:30:00 PM
- Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas • PR Newswire (US) • 05/14/2024 10:38:00 PM
- Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 05/13/2024 12:30:00 PM
- Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy • PR Newswire (US) • 03/26/2024 11:18:00 AM
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand • PR Newswire (US) • 03/11/2024 11:30:00 AM
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB • PR Newswire (US) • 02/23/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:30:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:04 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/02/2024 10:03:47 PM
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® • PR Newswire (US) • 01/02/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:24:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:20:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:18:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/29/2023 10:15:37 PM
- Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation • PR Newswire (US) • 12/11/2023 01:15:00 PM
- Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia • PR Newswire (US) • 12/11/2023 12:45:00 PM
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM